The EPS miss is severe but largely non-cash; focus on the NDA resubmission timeline and FDA feedback. Monitor for resubmission in Q4 2026 and any pre-approval warrant exercises. The $180M cash runway supports operations through potential approval in H1 2027.
Price Chart
Executive Summary
Achieve Life Sciences reported Q2 2026 EPS of -$0.80, significantly missing the consensus estimate of -$0.16, driven by a $48.7M non-cash charge from warrant liability revaluation. The company is advancing its cytisinicline NDA resubmission for Q4 2026 after a CRL, with a $180M upfront capital raise to fund commercialization. The stock will likely react to the EPS miss and the ongoing regulatory uncertainty despite the strong cash position.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.80 vs consensus -$0.16 (400% miss)
- Net loss of $74.8M includes $48.7M non-cash warrant liability charge
- Cash and securities at $187.3M after $180M private placement
- FDA CRL received June 2026; NDA resubmission planned for Q4 2026
- Potential FDA approval anticipated in H1 2027
- Cytisinicline manufacturing transitioned to Adare Pharma Solutions
Financial Impact
EPS miss of -$0.64 vs consensus; net loss of $74.8M for Q2 2026
Risk Factors
- FDA CRL may delay approval beyond H1 2027
- Warrant liability could cause further non-cash volatility
- Commercial launch execution risk for cytisinicline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342705 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 3 | $7.24 $7.19 | ▼ −0.69% | ▼ −0.27% | $6.54 (−9.67%) |
Oct 1, 2026 25d ago | 8-K | $7.24 $7.01 | ▼ −3.18% | ▼ −3.85% | $6.54 (−9.67%) |
Aug 14, 2026 10w ago | 8-K | $7.50 $7.52 | ▼ −0.27% | ▼ −0.94% | $6.54 (+12.80%) |
Aug 11, 2026 10w ago | 8-K | $6.69 $7.25 | ▲ +8.37% | ▲ +7.67% | $6.54 (−2.24%) |
Aug 11, 2026 10w ago | Press Release | $6.77 $6.69 | ▲ +1.18% | ▲ +1.43% | $6.54 (+3.40%) |
Aug 7, 2026 11w ago | Institutional Cluster | $6.65 $6.67 | ▲ +0.30% | ▲ +0.33% | $6.54 (−1.65%) |
Jun 11, 2026 19w ago | Institutional Cluster | $5.52 $5.52 | · 0.00% | ▲ +0.54% | $6.54 (−18.48%) |
Jun 2, 2026 20w ago | 8-K | $5.03 $4.92 | ▼ −2.19% | ▼ −1.49% | $6.54 (+30.02%) |
May 22, 2026 22w ago | EFFECT | $4.69 $4.56 | ▲ +2.77% | ▲ +3.36% | $6.54 (−39.45%) |
May 19, 2026 22w ago | Press Release | $4.45 $4.57 | ▲ +2.70% | ▲ +1.66% | $6.54 (+46.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers